Cramer dubs Regeneron stock a favourite after two FDA approvals invezz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from invezz.com Daily Mail and Mail on Sunday newspapers.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2023 Earnings Call Transcript August 3, 2023 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $10.24, expectations were $9.92. Operator: Welcome to the Regeneron Pharmaceuticals Second Quarter 2023 Earnings Conference Call. My name is Shannon and I will be your operator for today’s call. At this time, all participants […]
Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration.